KR960700741A - 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment) - Google Patents
인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment) Download PDFInfo
- Publication number
- KR960700741A KR960700741A KR1019950703297A KR19950703297A KR960700741A KR 960700741 A KR960700741 A KR 960700741A KR 1019950703297 A KR1019950703297 A KR 1019950703297A KR 19950703297 A KR19950703297 A KR 19950703297A KR 960700741 A KR960700741 A KR 960700741A
- Authority
- KR
- South Korea
- Prior art keywords
- thymosin
- composition
- dose
- human
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
본 발명은 인터페론 단독 치료에는 응답하지 않는, C형 간염 바이러스에 간염된 포유동물에 하나이상의 티모신 단독 또는 시스템 강화 티모신 단편을 면역 시스템 강화 양만큼 투여하는 C형 간염 치료방법에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (11)
- C형 간염 바이러스에 감염된, 인터페론 단독치료에 응답하지 않는 포유동물의 치료를 위한 약제제형의 제조에 사용하기 위하여 최소한 하나의 면역시스템-강화 양만큼의 티모신 또는 시스템-강화 티모신 단편을 포함하는 조성물
- 제1항에 있어서, 티모신이 티모신 프로렉 화이브, 티모신 α-1및 그 단편으로 이루어진 그룹으로부터 선택되는 조성물
- 제2항에 있어서, 상기 체형은 인간에 투여하기위해 제조되는데 약 900-1200㎎/㎡ 몸체 표면적의 용량으로 티모신 프랙션 화이브를 포함하는 조성물
- 제2항에 있어서, 상기 체형은 인간에 투여하기위해 제조되는데 약 900-1200㎎/㎡ 몸체 표면적의 용량으로 티모신 α-1의 약 1500-1700㎎/㎡의 용량으로 티모신 α-1또는 그 단편을 포함하는 조성물
- 제1항에 있어서, 상기 체형은 인간에 투여하기위해 제조되는데 티모신이 티모신 α-1의 약 1500-1700㎎/㎡의 용량으로의 티모신 α-1인 조성물
- 제1항에 있어서, 상기 제형이 약제학적으로 수용가능한 캐리어를 포함하는 조성물
- C형 간염 바이러스에 간염된, 인터페론 단독치료에 응답하지 않는 포유동물의 치료를 위한 약제제형의 제조에 사용하기 위하여 약제학적으로 수용가능한 캐리어에 최소한 하나의, 면역시스템-강화 양만큼의 티모신 또는 시스템-강화 티모신 단편을 포함하는 조성물
- 제7항에 있어서, 티모신이 티모신 프렉션 화이브, 티모신 α-1및 그 단편으로 이루어진 그룹으로부터 선택되는 조성물
- 제2항에 있어서, 상기 조성물은 인간을 치료하기 위한 것으로서 티모신이 약 900-1200㎎/㎡ 몸체 표면적의 용량으로의 티모신 프랙션 화이브인 조성물
- 제8항에 있어서, 인간을 치료하기 위한 것으로서 티모신이 900-1200㎎/㎡ 몸체 표면적의 용량으로 티모신 α-1또는 그 단편인인 조성물
- 제7항에 있어서, 인간을 치료하기 위한 것으로서 티모신이 티모신 α-1의 약 1500-1700㎎/㎡ 의 용량으로의 티모신 α-1인 조성물※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/027,500 | 1993-03-05 | ||
US08/027,500 US6001799A (en) | 1991-09-13 | 1993-03-05 | Method of treating hepatitis C in non-responders to interferon treatment |
US08/027500 | 1993-03-05 | ||
PCT/US1994/002320 WO1994020131A1 (en) | 1993-03-05 | 1994-03-03 | Method of treating hepatitis c in non-responders to interferon treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960700741A true KR960700741A (ko) | 1996-02-24 |
KR100306024B1 KR100306024B1 (ko) | 2001-11-30 |
Family
ID=21838079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950703297A KR100306024B1 (ko) | 1993-03-05 | 1994-03-03 | 인터페론치료에대한무반응자의c형간염치료조성물 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0687181B1 (ko) |
JP (1) | JPH06279309A (ko) |
KR (1) | KR100306024B1 (ko) |
CN (1) | CN1072961C (ko) |
AT (1) | ATE204760T1 (ko) |
AU (1) | AU683248B2 (ko) |
CA (1) | CA2157479C (ko) |
DE (1) | DE69428112T2 (ko) |
DK (1) | DK0687181T3 (ko) |
ES (1) | ES2162862T3 (ko) |
FI (1) | FI954127A (ko) |
GR (1) | GR3037021T3 (ko) |
MY (1) | MY121198A (ko) |
NO (1) | NO320877B1 (ko) |
PT (1) | PT687181E (ko) |
SG (1) | SG64894A1 (ko) |
WO (1) | WO1994020131A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0858343B1 (en) | 1995-11-02 | 2004-03-31 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
CN1461221A (zh) * | 2000-08-07 | 2003-12-10 | 希克龙制药公司 | 使用胸腺素和聚乙二醇化干扰素治疗丙型肝炎 |
CA2520400C (en) | 2003-03-28 | 2013-02-19 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
ES2389452T3 (es) * | 2006-05-02 | 2012-10-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de timosina 1, sola o en combinación con PTX3 o ganciclovir, para el tratamiento de infección por citomegalovirus |
EP2421970B1 (en) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
JP2012526149A (ja) | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
TW224053B (ko) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1993
- 1993-09-27 CN CN93119345A patent/CN1072961C/zh not_active Expired - Lifetime
- 1993-12-27 JP JP5331601A patent/JPH06279309A/ja active Pending
-
1994
- 1994-02-18 MY MYPI94000381A patent/MY121198A/en unknown
- 1994-03-03 SG SG1996005604A patent/SG64894A1/en unknown
- 1994-03-03 DK DK94910226T patent/DK0687181T3/da active
- 1994-03-03 EP EP94910226A patent/EP0687181B1/en not_active Expired - Lifetime
- 1994-03-03 KR KR1019950703297A patent/KR100306024B1/ko not_active IP Right Cessation
- 1994-03-03 AU AU62759/94A patent/AU683248B2/en not_active Ceased
- 1994-03-03 ES ES94910226T patent/ES2162862T3/es not_active Expired - Lifetime
- 1994-03-03 PT PT94910226T patent/PT687181E/pt unknown
- 1994-03-03 DE DE69428112T patent/DE69428112T2/de not_active Expired - Lifetime
- 1994-03-03 AT AT94910226T patent/ATE204760T1/de active
- 1994-03-03 CA CA002157479A patent/CA2157479C/en not_active Expired - Fee Related
- 1994-03-03 WO PCT/US1994/002320 patent/WO1994020131A1/en active IP Right Grant
-
1995
- 1995-09-04 FI FI954127A patent/FI954127A/fi unknown
- 1995-09-04 NO NO19953473A patent/NO320877B1/no not_active IP Right Cessation
-
2001
- 2001-10-25 GR GR20010401892T patent/GR3037021T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR100306024B1 (ko) | 2001-11-30 |
ES2162862T3 (es) | 2002-01-16 |
NO320877B1 (no) | 2006-02-06 |
AU6275994A (en) | 1994-09-26 |
CA2157479A1 (en) | 1994-09-15 |
MY121198A (en) | 2006-01-28 |
CA2157479C (en) | 2000-08-08 |
EP0687181A1 (en) | 1995-12-20 |
ATE204760T1 (de) | 2001-09-15 |
CN1072961C (zh) | 2001-10-17 |
GR3037021T3 (en) | 2002-01-31 |
WO1994020131A1 (en) | 1994-09-15 |
NO953473L (no) | 1995-09-04 |
AU683248B2 (en) | 1997-11-06 |
DK0687181T3 (da) | 2001-10-01 |
DE69428112D1 (de) | 2001-10-04 |
CN1092322A (zh) | 1994-09-21 |
JPH06279309A (ja) | 1994-10-04 |
PT687181E (pt) | 2002-01-30 |
SG64894A1 (en) | 1999-05-25 |
EP0687181B1 (en) | 2001-08-29 |
DE69428112T2 (de) | 2002-03-21 |
NO953473D0 (no) | 1995-09-04 |
FI954127A0 (fi) | 1995-09-04 |
FI954127A (fi) | 1995-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0003131A2 (hu) | Polietilénglikol/alfa-interferon konjugátumok fertőzés kezelésére | |
EP1669364A3 (en) | Methods and compositions for treating hepatitis C virus | |
EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
RU94022480A (ru) | Способ лечения гепатита, композиция, усиливающая ин виво инактивацию вируса гепатита с, препарат для лечения гепатита с | |
DE69129248D1 (de) | Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen | |
EA199901031A1 (ru) | Производные бензимидазола | |
BR9811121A (pt) | Produto, composição farmacêutica, e uso de um produto | |
CA2111580A1 (fr) | Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant | |
DE69521693D1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
DE3669106D1 (de) | Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe. | |
KR960700741A (ko) | 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment) | |
PT101444A (pt) | Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao | |
EA200400592A1 (ru) | КОНЪЮГАТЫ ПЕПТИДА ТИМОЗИН α1 И ПОЛИМЕРА | |
ATE67783T1 (de) | Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen. | |
KR960705578A (ko) | 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) | |
EA199900345A1 (ru) | Фармацевтические композиции, содержащие ламивудин и зидовудин | |
ATE58478T1 (de) | Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom. | |
DE68900926D1 (de) | Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen. | |
FI924215A0 (fi) | Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen. | |
RU94045140A (ru) | Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний | |
DE69706657D1 (de) | Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen | |
NO302360B1 (no) | NG-monometyl-L-argininhydrokloridderivater | |
ATE348628T1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
ATE64855T1 (de) | Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom. | |
KR950031082A (ko) | 우르소데옥시콜린산의 신규한 유도체와 이를 포함하는 제약학적 성분물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110722 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |